23 AndMe founder Anne Wojcicki spoke at a supervisory and government reform hearing in Washington, DC on June 10, 2025.
Andrew Harnik | Getty Images
Anne Wojcicki, co-founder and former CEO of 23andme, has regained control of the embattled genetic testing company after her new nonprofit, TTAM Research Institute (Outbid). Regeneron Pharmaceuticalscompany Announce Friday.
TTAM will acquire all assets of 23AndMe for $305 million, including its personal genome services and research services business line and telemedicine subsidiary Lemonad Health. It was a huge victory for Wojcicki. Application Chapter 11 Bankruptcy protection in March.
Last month, Regeneron announced that it would buy most of 23AndMe’s assets for $226 million in a bankruptcy auction. But Wojcicki submitted a separate $305 million bid through TTAM and pushed for a reopening of auctions. TTAM is the acronym for the acronym of 23andme. The Wall Street Journal.
“I am pleased that the TTAM Institute will continue to carry out the 23andMe task to help people gain, understand and benefit from the human genome,” Wojcicki said in a statement.
23AndMe gained popularity thanks to its at-home DNA testing kit, giving customers an idea of their family history and genetic characteristics. Five times CNBC Slayer 50 company Public In 2021, it will be merged with a special purpose acquisition company. At its peak, 23AndMe is worth about $6 billion.
The company strives to generate frequent occurrences of revenue and stands up to viable research and treatment businesses after it is open and has plagued privacy concerns since then Hackers accessed information Nearly 7 million customers in 2023.
TTAM’s acquisition still requires approval from the U.S. Bankruptcy Court for Eastern Missouri.
